Comparative Pharmacology
Head-to-head clinical analysis: PARSABIV versus SENSIPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARSABIV versus SENSIPAR.
PARSABIV vs SENSIPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium-sensing receptor (CaSR) agonist; increases the sensitivity of the CaSR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target iPTH reduction.
None Documented
None Documented
Terminal elimination half-life of 3-5 days, supporting once-weekly subcutaneous dosing.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Renal: negligible (<2% unchanged); fecal: primary route via biliary elimination of intact drug and metabolites; not dialyzable.
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
Category C
Category C
Calcimimetic
Calcimimetic